Life Science & Medical Timeline Compression

[DD+POD] Dr Reddy's generic twice-yearly lenacapavir receives tentative FDA approval under 16 months after the original, targeting $40 annual HIV prevention across 120 countries; licensing excludes at least 26 middle-income jurisdictions.

[DD+POD] EMBL, DKFZ and Sanger researchers map glioblastoma cell-state regulation across over one million cells; increasing MYT1L reduces tumor growth and invasion and extends survival in mice.

[DD] Open structRFM, trained on 21 million RNA sequence-structure pairs, supports Zfold predictions comparable to AlphaFold3 across three benchmarks, with dataset, weights and code released.

[DD] Anthropic reports Claude-assisted purification of a prokaryotic vault particle fell from about three days to 90 minutes, enabling its first 3D cryo-EM map; biological function remains unknown.

[DD+TCR] Hannover and Shanghai report base-editing seven alpha-1 antitrypsin deficiency patients; a published liver biopsy confirms correction in one recipient, off weekly replacement infusions since March.

[DD+POD] Exin Therapeutics reports an AI-selected gene therapy delivered robotically to an epileptic mouse under veterinary supervision; whether treatment reduces seizures remains unknown.

[SCAN+TCR] MIT researchers used implanted magnetic beads to track muscle length and speed in three people with below-knee amputations, outperforming skin and implanted electrodes for prosthetic cursor control.

[SCAN+TCR] UCSF's brain-activated engineered CAR-T cells cleared diffuse midline glioma and rejected repeat tumors in mice; a human trial is planned for April 2027.

[DD+TCR] Roche's divarasib cut death risk 44% versus the approved drugs sotorasib and adagrasib in a 338-patient Phase 3 KRAS G12C lung cancer trial, extending median survival to 17.7 months from 12.0.

[DD+POD] Interim Phase 3 DeLLphi-305 results in 563 patients found Imdelltra plus Imfinzi extended median small cell lung cancer survival to 21.1 months versus 12.7; serious treatment-related adverse events reached 20.9% versus 10.8%.

[DD+POD] Microsoft's MAI-DxO solved 83% of complex simulated cases versus generalists' 36%; GPT-5 alone reached 78.9%, and prospective clinical validation remains ahead.

[DD+POD] Intismeran autogene plus Keytruda cut melanoma recurrence or death 42% in a Phase 3 trial exceeding 1,100 patients; two-year recurrence-free survival reached 82.2% versus 70%.

[SCAN+TCR] Pinal generated proteins from written descriptions of four functions, with laboratory tests confirming all four worked.

[DD+TCR] Radical Numerics reported Omnii-1-designed phages administered to a patient with an antibiotic-resistant infection through authorized compassionate use; clinical outcomes remain undisclosed.

[DD] Contract laboratories found 17 scorpion-toxin binders among 211 tested Claude-assisted protein designs; Anthropic released the tested designs and experimental data.

[DD] UW and Nvidia released BSD-3-licensed RFD4-Proteina, reporting five to ten times faster candidate generation and computational design success, with laboratory validation across several tasks.

[DD] A Nature study combined designed protein scaffolds with synthetic metal catalysts to demonstrate recyclable, light-driven reactions preferentially producing one molecular mirror image.

[SCAN+TCR] A UK digital-first GLP-1 observational program enrolled 8,127 women; 7,297 with six-month measurements averaged 15.5% weight loss, with similar results across income levels and 91.4% remaining enrolled.

[SCAN+TCR] A preprint reports pig kidneys vitrified at -150°C for up to one year were magnetically rewarmed and transplanted into pigs, where they produced urine; long-term survival remains undemonstrated.

[SCAN+TCR] AI-assisted scan analysis across 101,243 cancer-center patients linked brown fat to less cardiovascular and psychiatric disease; losartan increased brown-fat activity in mice.

[DD+POD] MIT nanoparticles reprogrammed up to 80% of targeted natural killer cells inside mice, producing melanoma remission in three of five animals and clearing T cell lymphoma without external cell manufacturing.

[DD] Google offered up to 200 European researchers access to five science models, including AlphaFold 3 and AlphaGenome, with $3M in compute credits and company-selected admission.

[DD+TCR] An automated workflow called OSAR used liquid-handling robots and yeast recombination to assemble 31 of 34 bacterial gene clusters up to 78 kilobases without custom DNA synthesis, expressing 29 peptides from 10 clusters.

[SCAN+TCR] Prime-editing cell recorders traced mouse development from a fertilized egg, reconstructing the lineage of 1.3 million embryo cells in one of two new studies.

[DD+POD] Biohub announced a $1.8 billion virtual-cell initiative, including $300 million from Google DeepMind, Meta and Isomorphic Labs and more than $500 million from DOE over five years.

[SCAN+TCR] A light-activated gene-therapy trial reported restoration of aspects of visual function in the New England Journal of Medicine.

[SCAN+TCR] Neuralink pretrained its brain-computer-interface decoders on 50,000 hours of unlabeled recordings, reporting weeks of stable cursor control without recalibration in some participants and a peak result of 11.32 bits per second.

[SCAN+TCR] A urine liquid biopsy reading cell-free RNA detected localized bladder cancer at 95% sensitivity across 683 samples and forecast which patients would respond to BCG immunotherapy versus chemotherapy.

[DD+POD] FDA approved Edwards Lifesciences' AUTUS pediatric pulmonary valve, adjustable by catheter from about 13 to 22 mm; a 62-patient study reported no replacements through one year, with only two expansions performed so far.

[SCAN+TCR] An AI speech clock estimated biological aging from four minutes of voice in 2,928 Spanish-speaking adults; its age gap tracked brain atrophy and Alzheimer's blood markers.

[DD+POD] A lipid screened specifically for large gene-editor cargo delivered base editors to 48% of mouse brain cells and 27% of lung cells, while a light- and inflammation-triggered viral vector reached injured heart tissue, breaking gene therapy's decades-long confinement to mostly liver-only delivery.

[DD] AI-guided reformulation let mRNA vaccines hold full potency for a year at room temperature or two months at 98 degrees F in mice, matching a standard shot's immune response and confirmed in primates and dissolving microneedle patches.

[SCAN+TCR] A rapid DNA test piloted across five NHS sites is cutting suspected brain tumor diagnosis from weeks to days.

[SCAN+TCR] Structural modeling of 44 Bundibugyo virus genomes predicted MBP134 remains protective against the 2026 outbreak while Ebanga's antibody binding may be compromised.

[DD+POD] MIT researchers used language tied to 49 risk factors to classify about 16,000 crisis-text conversations, releasing an open tool that shows counselors the words behind each estimate; it has not been validated to predict suicide attempts.

[DD+POD] MIT researchers built an autonomous system that assembles and measures the lipid nanoparticle shells used to deliver RNA therapies, tuning particle size and shape in real time to hit organ-targeting specifications no prior manual method could reliably control.

[SCAN+TCR] AlphaFold added about 8,000 predicted viral protein-pair structures from 23 human-health-relevant virus families to a free pandemic-preparedness portal.

[DD+POD] Anthropic's Claude agents identified a previously unrecognized CRISPR-like repeat system after screening more than 200,000 enzymes in 21 hours; its biological function remains unknown.

[DD+POD] GRAIL's Galleri detected signals across 17 cancer types in a 35,878-person prospective study, with 99.64% specificity but 39% overall sensitivity; an FDA advisory panel backed its benefits 7 to 2.

[SCAN+TCR] The EAGLE model detected esophageal cancer from ordinary chest CT scans at 90% sensitivity and 98.5% specificity across validation spanning 12 centers, 80,612 patients, and three countries. [Source](https://www.nature.com/articles/s41591-026-04656-4)

[SCAN+POD] The 142,250-person NHS-Galleri trial missed its primary endpoint of reducing stage III and IV cancer diagnoses, though the blood test detected 937 tumors and secondary analysis found fewer stage IV cancers. [Source](https://www.nature.com/articles/s41591-026-04652-8)

[DD+POD] CRMA-1001 epigenetically silenced hepatitis B without cutting DNA, reducing viral biomarkers over 1,000-fold after one mouse dose and leaving up to 90% of treated animals antigen-free after three doses; human testing has begun.

[DD+POD] A follow-up analysis of the RIO trial found two long-acting broadly neutralizing antibodies, paired with patients' own immune response, associated with an estimated 36-week half-life for the intact HIV reservoir versus four to seven years on standard therapy, with one participant off daily treatment past 160 weeks.

[DD+POD] Alibaba's DAMO Academy published RADAR, an open-source model reading a single abdominal CT for 146 diseases across 18 organs, beating 23 of 26 specialist radiologists and lifting junior readers to senior-level accuracy.

[DD+POD] Anthropic confirmed a Bay Area wet lab where Claude directs robotic biology experiments, extending its roughly $400 million Coefficient Bio acquisition and Claude Science platform into physical validation.

[DD+POD] Novo Nordisk, down about 20% over the past year, partnered with Anthropic to apply Claude Science's biological-reasoning tools directly to drug discovery rather than back-office work; a Stanford spinout separately ran a 37,000-agent virtual biotech company with no humans that analyzed 50,000 clinical trials in under a week.

[DD+POD] Stanford researchers emptied a mouse's developing cortex and transplanted human brain organoids that grew fivefold to fill over 90% of the space and wired into the animal's nervous system, opening a living model for studying human cortical development.

[DD+TCR] A single-draw blood test combining microRNA signatures with a standard protein marker caught stage 1 and 2 pancreatic cancer 87% of the time across a 1,785-person study spanning four countries.

[DD+POD] Five-firm AI Structural Biology Network pooled 20,167 proprietary protein-ligand structures to fine-tune OpenFold3, beating public and single-firm models on held-out cases, while the resulting model remains unpublished and unavailable outside the consortium.

[DD+POD] The OpenAI Foundation launched Public Data for Health, funding $40M for open cancer-vaccine data at UNC and $500K to preserve failed biotechs' regulatory filings, positioning open biomedical datasets against proprietary pools like the AI Structural Biology Network's.

[DD+POD] Insilico Medicine proposed a Longevity Vaccines research program using AI-chosen targets and circular mRNA lipid nanoparticles to transiently arm a patient's own T cells against senescent and other aging-driver cells, starting with immune rejuvenation; no candidate, preclinical data, or trial yet disclosed.

[DD+POD] UCSF researchers built a single brain implant with roughly 253 surface electrodes that simultaneously decoded intended speech into on-screen text and intended gestures into an animated avatar, the first BCI to translate verbal and non-verbal communication at once.

[DD+POD] University of Miami researchers used AI shape comparison across more than 214 million predicted proteins to identify TM184C, a hidden GPCR-family receptor that builds cell-to-cell bridges sharing mitochondria, cargo, and fuel, with a yeast ortholog roughly a billion years old.

[DD+POD] Wuhan University researchers densely armored guide RNA along its full length rather than just its ends, reaching nearly 70% prime editing efficiency in mouse liver from a single injection at a clinically translatable dose, roughly an 80-fold gain over conventional guides.

[DD+POD] One infusion of fucose-coated autologous bone-marrow cells reduced fractures from one every year or two to roughly one per decade across ten women with advanced osteoporosis.

[DD+POD] Magnetically activated injectable nanoantennas killed 52.2% of chemotherapy-resistant patient-derived glioblastoma cells and extended median mouse survival by more than 50% while sparing healthy brain tissue.

[DD+POD] Google DeepMind released a free precomputed AlphaGenome Atlas mapping predicted molecular effects for all nine billion possible single-letter human genome mutations, already helping Broad Institute researchers flag a non-coding variant tied to a severe epilepsy case.

[DD+POD] Six independently built proteomic aging clocks all read lower biological age in stored blood from a completed pulmonary fibrosis trial of an AI-designed drug, opening a way to test whether disease drugs also slow aging without a separate decades-long study.

[DD+POD] A clinical AI agent trained on 4.4 million longitudinal visits and externally validated on independent cohorts forecast maternal and infant disease risk from routine records, reaching 0.91 AUROC for preterm labor.

[SCAN+TCR] FDA approved Zanvastro (Ionis), the first disease-modifying therapy for Alexander disease, after treated patients held walking speed steady while the untreated control group declined 33%.

[DD+POD] Late-life semaglutide treatment extended median lifespan in older female mice from 742 to 834 days, about 12%, while improving muscle strength, cognition, inflammation, senescence, and mitochondrial function.

[DD+POD] ChatGPT Health connected to Epic for authorized read-only synthesis of records across a system holding data for more than 325 million patients, alongside PubMed, CMS, RxNorm, and DailyMed sources.

[DD+POD] Anthropic reported Mythos 5.1 designed viable high-affinity protein binders for nearly 50% of candidates across 12 targets, versus typical campaign rates of 10% to 15%.

[DD+TCR] A donor-complementary prime editing method (DoPE) inserted DNA sequences up to 12.5 kilobases into a chosen genomic site without cutting both DNA strands, correcting PRKCSH mutations tied to polycystic liver disease in cultured cells.

[SCAN+TCR] UCSF researchers built the largest molecular interaction map of autism, showing hundreds of risk genes and dozens of mutations converge within a small number of shared protein networks.

[DD+POD] A single CD19 CAR-T infusion improved all six patients with severe treatment-refractory rheumatoid arthritis after up to eight failed drugs, putting three into medication-free remission in a phase 1 trial.

[DD+POD] A machine-learning model analyzed 97,364 mammograms from 29,921 women and detected prior stroke with 86% accuracy, high blood pressure with 79%, and coronary heart disease with 78%.

[SCAN+TCR] FDA authorized Abbott's Libre Duo 10 Day, the first wearable continuously monitoring both glucose and ketones to flag rising diabetic ketoacidosis risk.

[DD+POD] FDA approved daraxonrasib, the first RAS-targeted pancreatic cancer drug, after a 500-patient trial nearly doubled median survival from 6.7 to 13.2 months.

[DD+POD] AI color-coded nerves and vessels from live endoscope footage during removal of an 11mm pituitary tumor, helping London surgeons preserve a patient's sight.

[DD+POD] A designed pan-Ebolavirus antibody cocktail, MBP134, cured an infected health worker and, given as post-exposure prophylaxis, protected four exposed children during the DRC's deadliest-ever Bundibugyo Ebola outbreak, per two Nature Medicine papers.

[DD+POD] EvoMax, an AI-guided protein evolution pipeline, designed a compact gene editor (FanzMAX v3-hLa) that edited human genes up to 97% efficiency from sparse data, beating prior compact editors more than 2.6-fold with an 84% design hit rate.

[SCAN+TCR] FDA approved the first blood test for detecting Alzheimer's disease biomarkers, developed by Roche and Eli Lilly.

[SCAN+TCR] AI identified antibody signatures across more than 4,000 people that predict how strongly someone will respond to a vaccine before they receive the shot.

[DD+POD] A cell-free bypass conduit stayed fully open in sheep for 18+ months off blood thinners (Nature Communications), while a 20-patient Nature Medicine trial found stem-cell-derived heart muscle injections improved perfusion and wall thickening in advanced heart failure despite universal early arrhythmia.

[DD+POD] A blinded, prospective AIntibody benchmark of 511 AI-designed antibodies from 29 organizations found top affinity-maturation submissions reaching ~95 pM but no single method generalizing across design tasks, with only 0.6% of Challenge 1 submissions clearing sub-100 pM.

[DD+POD] Moderna and Merck’s individualized mRNA therapy plus Keytruda met recurrence-free and distant-metastasis-free survival endpoints in a 1,137-patient Phase 3 melanoma trial, the neoantigen vaccine class’s first late-stage success.

[SCAN+TCR] Claude designed working protein binders against 14 of 15 targets, achieving 22 to 35% binding rates versus the 10 to 15% typical of current campaigns.

[DD+POD] FDA approved Bristol Myers Squibb's iberdomide (Zenbexus), the first drug in a new oral class for relapsed multiple myeloma, cleared using a more sensitive minimal-residual-disease remission threshold.

[DD+POD] Four Nature papers identified GNAS-mediated T-cell exhaustion in tumors, generated CAR-T cells in vivo, produced seven AI-designed surface anchors matching or beating natural designs, and blocked myeloma escape with CAR-iNKT cells.

[DD+TCR] GIFT, an engineered oral probiotic, sensed high glucose and secreted corrective peptide doses in diabetic mice and primates while clearing from the gut within roughly five days.

[SCAN+TCR] UK regulators approved Foundayo/orforglipron, Europe’s first daily oral GLP-1, for adult weight management and type 2 diabetes.

[DD+POD] Google’s AMIE conducted real-time video consultations, interpreting audiovisual cues and virtual exams while specialist raters scored it favorably against primary-care physicians and patient actors preferred it to text chat.

[SCAN+TCR] MRICombo, a single deep-learning model, segments anatomy, grades gliomas, and stages cancers across nine MRI sequence types, collapsing dozens of task-specific diagnostic systems into one (Nature Communications).

[DD+POD] Intracranial B7-H3 CAR-T therapy delivered 72 infusions across 15 recurrent glioblastoma patients with no dose-limiting toxicity, reaching 66.7% one-year survival and 19.1-month median overall survival (Nature Medicine).

[DD] Companion phosphoproteomic mapping (INSIGHT) showed disseminating glioblastoma cells rewire toward mesenchymal and neural-progenitor signaling states at the tumor margin, flagging hornerin and a phosphorylated glutamate receptor subunit as candidate targets (Nature Communications).

[DD+POD] Stanford and Arc Institute researchers used generative AI to design 16 novel functional bacteriophage genomes that were synthesized and revived against E. coli.

[SCAN+TCR] FDA granted accelerated approval to Replimune’s twice-rejected melanoma therapy RP1 as Phase 3 177Lu-PSMA-617 prolonged progression-free survival in metastatic prostate cancer.

[DD+POD] FDA approved Moderna’s mFlusiva, the first US mRNA flu vaccine, after a 40,000-person trial found roughly 27% greater efficacy than a standard shot.

[DD+POD] The Telomere-to-Telomere Consortium completed both parental chromosome sets of living donor HG002, adding 900M+ bases and revealing roughly 15% beyond the standard human reference.

[DD+POD] The Human Cancer Models Initiative released 665 patient-derived models across 25 cancers, including 153 rare-cancer models, with matched samples showing 97.8% genetic and 95% epigenetic concordance.

[DD+POD] REAP improved cytochrome P450 activity 57-fold and a protein-stitching bacterial enzyme up to 104-fold in five AI-guided robotic cycles.

[DD+POD] PandaOmics surfaced targets for rare sinonasal cancer while a stem-cell 3D brain model reproduced Alzheimer’s pathology and advanced toward automated drug screening.

[DD+TCR] AI improved skin-disease diagnosis for novices and clinicians, but novices followed confident errors while experts caught them; fairness constraints narrowed performance gaps across skin tones.

[SCAN+TCR] An AI model extracted mortality and cognitive-decline signals from routine sleep studies, dividing patients into five risk tiers missed by conventional apnea metrics.

[DD+POD] Researchers used phage-assisted continuous evolution to redirect botulinum neurotoxin X proteases toward activating procaspase-1 and gasdermin D, selectively killing cultured cancer cells and slowing tumor growth in a drug-resistant pancreatic cancer mouse model (Nature Biotechnology).

[DD+POD] UC Berkeley's 48-sensor computational microscope captured 25.2 billion pixels/second at 3-micron resolution across 5cm² of living C. elegans, breaking the resolution-field-of-view-speed trade-off that has constrained optical microscopy.

[DD+POD] Stanford NLP models analyzing sentence structure in 204 children ages 9 to 13 predicted psychiatric diagnoses six years ahead more accurately than expert clinical panels.

[DD+TCR] An eight-week randomized trial of 50 adults found oral semaglutide reduced heavy-drinking days, drinks per occasion, cravings, alcohol-related problems, and cannabis-use days.

[DD+POD] An agent-guided workflow designed the ViscoClamp peptide hydrogel, restoring bone-repair signaling across rats, rabbits, beagles, and rhesus macaques.

[DD+TCR] A two-model framework predicted acute kidney injury 24 hours ahead across 140,637 admissions, reaching 0.95 internal AUC and 0.68 positive predictive value while identifying modifiable risks.

[DD+POD] Retina4IRD, a vision transformer trained on 1,843 patients, lifted specialists' top-5 inherited-retinal-disease genotype accuracy from 67.3% to 88.5% in a 295-patient randomized trial reading genotype directly from retinal images.

[DD+POD] Researchers used AlphaFold to identify the protein regions responsible for CRISPR off-target edits and redesigned them to cut error rates while preserving intended edits, published in Nature.

[DD+POD] Science Corporation's PRIMA retinal implant won EU CE Mark clearance, the first BCI cleared for form vision, restoring reading ability with a mean 25.5-letter improvement and 84% of the 38-patient trial cohort regaining ability to read letters, numbers, and words.

[DD+TCR] Texas A&M team supercooled pig kidneys at -4°C without cryoprotectants for up to 72 hours, then successfully transplanted them with immediate function - triple the clinical cold-storage standard.

[DD+POD] KNIT inserted >10-kb DNA at up to 89% without double-strand breaks and built nonviral CAR-T cells; ContactSeek improved off-target discrimination, while a compact single-vector editor improved SMA in mice.

[DD+POD] ProteinMPNN redesigned three proteases; 58 of 74 designs functioned, and evolution from stabilized variants produced an ataxin-2 protease 79× more selective than the best natural-starting version.

[SCAN+TCR] Veteran genetic-medicine scientists launched a center to turn personalized CRISPR treatments modeled on Baby KJ’s custom therapy into a repeatable development pathway.

[DD+POD] A phase 1 trial (Nature Medicine) found iPSC-derived neural stem cell transplants produced a median 13-point motor score improvement in four complete cervical spinal cord injury patients, with two converting ASIA impairment grades and no tumors across 2-4 years of follow-up.

[DD+TCR] KAIST researchers (Science Immunology, July 10) found anti-CTLA-4 glioma immunotherapy depends on B-cell antibody responses generated in deep cervical neck lymph nodes rather than the tumor site, with tumor reduction vanishing entirely in B-cell-deficient mice.

[DD+POD] Duke researchers (Nature Communications) aligned speech-BCI neural recordings from multiple patients into a shared latent space; a decoder trained on the pooled cross-patient data beat patient-specific models, dissolving the months-long per-user calibration bottleneck.

[DD+POD] FDA approved Merck's Lipfendra, the first oral cholesterol pill matching injectable-level LDL reduction efficacy, removing the needle-hesitancy barrier that capped adoption of the most aggressive cholesterol therapies.

[DD+POD] Double neural bypass (Feinstein Institutes, Nature Medicine) restored arm strength (+86%/+62%) and touch sensation in a man paralyzed six years, with gains persisting after a 3-month stimulation halt.

[DD+POD] Doudna-lab AI-designed synthetic TnpB-derived CRISPR enzymes edited human genes more efficiently than their natural counterparts, alongside a companion minimal RNA-guided nuclease design, published in Science.

[DD+TCR] TGFβ-armored GPC3 CAR-T cells drove tumor regression in 32 of 36 refractory liver-cancer patients; objective response reached 44.4%, median survival 14.2 months, and median response duration 4.4 months.

[DD+POD] MIT mechanically stimulated endothelial tissue through magnetized gel to steer branching artificial blood vessels, with 5% stretch producing many vessels and 15% producing fewer, longer branches.

[DD+POD] ProLM analyzed plasma proteins from 15,499 UK Biobank participants to predict 16 chronic diseases, detecting signals including GDF15 more than 15 years before diagnosis and validating in the China Kadoorie Biobank.

[DD+TCR] Technical University of Denmark and ORCA Computing paired a generative model with a printer-sized photonic quantum computer to design peptides that bound their targets in lab tests, with the largest gains where training data was scarcest.

[DD+POD] A liposomal KRAS-G12D inhibitor (HRS-4642) drove a 63.3% response rate in metastatic pancreatic cancer and LAG-3 blockade lifted recurrent-glioblastoma 12-month survival to 52.2% vs. 34.8%, both in *Nature Medicine* phase 1 trials.

[DD+POD] NeuroVFM, trained on 5.24 million real hospital brain scans via self-supervised Vol-JEPA, beat GPT-5 in live hospital triage (92.68% vs. 71.2% accuracy) and cut radiology report-generation errors roughly in half.

[DD+TCR] STEM-PD's off-the-shelf stem-cell-derived dopaminergic progenitor therapy cleared its 12-month phase 1/2 safety endpoint in 8 Parkinson's patients with no tumors or graft-induced dyskinesias, though one patient died of an immunosuppression-linked fungal infection.

[DD+POD] A Nature feasibility study (UC San Diego) found humanoid robots using standard laparoscopic instruments - not purpose-built surgical hardware - completed a live porcine cholecystectomy via teleoperation, benchmarked against the da Vinci system.

[SCAN+TCR] A bispecific broadly neutralizing HIV antibody cleared first-in-human Phase 1 testing, safe and well tolerated across 54 participants with and without HIV.

[DD+POD] AI-guided CRISPR screen (VirtualCRISPR framework plus genome-wide keratinocyte knockout screen) identified ALOX5 and OXTR as psoriasis targets; topical zileuton plus cligosiban matched injected anti-IL17RA biologic efficacy in mice.

[SCAN+TCR] NHS app began AI triage routing patients toward GP, pharmacy, or A&E care, reaching 200,000 patients over the next year.

[DD+TCR] EU approved Novartis's Itvisma, an intrathecal SMA gene therapy, from age 2 into adulthood; Median Technologies' eyonis LCS AI lung-cancer screening software received CE marking after earlier FDA clearance; India moved to bring stem-cell and gene therapies under central licensing.

[SCAN+TCR] Closed-loop intracranial BCI reading anterior insula activity causally steered human value-based decisions via sub-second neural fluctuations (Nature Communications).

[DD+POD] King's College London/McMaster dual-target GPNMB CAR-T cleared glioblastoma tumors and their protective tumor-associated macrophages simultaneously, durable past 160 days in mouse models; separately, ZSNeo-DC personalized neoantigen dendritic-cell vaccine Phase 1b showed 100% one-year survival and 16.2-month median PFS in 11 patients.

[DD+POD] Conception (Berkeley) reports the first early human eggs derived entirely from stem cells (iPSCs to primordial germ cells to lab-grown mini-ovaries producing follicles), advancing in vitro gametogenesis; still early-stage, no viable egg or pregnancy demonstrated yet.

[DD+POD] Nature Medicine: COMPASS pan-cancer foundation model predicts immunotherapy response across 33 tumor types from a single transcriptome, beating 22 existing methods across 16 cohorts (8.5% accuracy gain, hazard ratio 4.7 for survival); Insilico Medicine signed a ~$660M Takeda deal for AI-discovered drug candidates (31 now in development).

[DD+POD] SpudCell: 36-gene synthetic cell designed from first principles, open-sourced via Biotic nonprofit: marks transition from editing biological systems to constructing life from designed parts; AlphaFold database mined for radical halogenases (new chemistry class); Nature paper deploys AI agent to run full yeast-cell simulation across 8 functional modules with closed experimental loop; Conception demonstrates stem-cell mini-ovaries achieving oocyte maturation.

[SCAN+TCR] FDA approves Tregzi; Casgevy sickle-cell gene therapy expanded to children as young as age 2; Brain2Qwerty v2 reaches 61% neural decoding accuracy; Neuralink announces transdural BCI trial; neuromorphic hearing aid demonstrated.

[SCAN+TCR] FDA approves Tregzi (first regulatory T-cell therapy for graft-versus-host disease); Casgevy sickle-cell gene therapy expanded to children as young as age 2; Brain2Qwerty v2 reaches 61% word decoding accuracy from noninvasive MEG; Neuralink announces first transdural BCI implant; neuromorphic hearing aid demonstrated.

[DD+POD] Anthropic launched Claude Science with autonomous drug-discovery and genomics/proteomics/cheminformatics tools available to any subscriber - marking commercial-scale deployment of AI-directed scientific research pipelines.

[SCAN] Meta Brain2Qwerty v2 achieved 61% word accuracy decoding speech intent from non-invasive MEG (vs ~8% for prior approaches); code publicly released.

[DD+TCR] HemaGuide, a locally deployable agent grounded in 2,000+ real tumor-board cases, matched subspecialty hematology decisions at 82.8% concordance across 664 cases in 39-second median inference on commodity hardware, with 0.3% hallucination rate; resident physicians working alongside it reached near-senior concordance in several subspecialty areas, compressing room-bound expert deliberation into a community-deployable tool.

[DD+TCR] Medicare began covering GLP-1 obesity drugs July 1 at a $50 copay (first coverage in program history), opening access to several million seniors with eligible conditions including prediabetes and uncontrolled hypertension; 82% of eligible beneficiaries are unaware; program expires end of 2027 absent extension or legislative change.

[DD+POD] EpiCRISPR's EPI-321, an epigenetic therapy silencing DUX4 without altering DNA, showed the first three evaluable FSHD patients gaining lean muscle volume at 6 months (average ~370 mL; individual muscles up to 15%+ growth), reversing the established disease trajectory in a condition with no approved therapy; Phase 1/2 trial enrolled 9 patients across two dose cohorts, primary readout expected mid-2027.

[DD+POD] A retargeted large serine recombinase (Bxb1 variant, Nature Biotechnology) demonstrated precise integration of large DNA payload sequences at chosen genomic locations (engineered to abandon its natural landing site for selected targets), extending precision genome writing beyond CRISPR's cut-and-repair paradigm to large-insert operations without cutting DNA.

[DD+TCR] Founder Connor Christou navigated a one-in-420,000 non-Hodgkin's lymphoma using Claude across 12 oncologist consultations; the model flagged thymus reactivation as a PET scan confound in an ambiguous post-treatment scan that physicians were considering for radiotherapy: first documented patient-led bedside AI collaboration in a disease most specialists see once per career.

[DD+TCR] Nature Medicine adversarial study found leading health AI models including GPT-5 and Gemini fabricate convincing but flawed reasoning under slight prompt changes, with popular health benchmarks varying widely in what they actually measure: maps the specific conditions under which clinical AI reasoning degrades and sets design criteria for verification.

[DD+TCR] Human transgenes TNFAIP3 and HMOX1 added to triple-knockout pig kidneys markedly prolonged xenograft survival in nonhuman primates, reducing T-cell infiltration and rejection gene expression, narrowing xenotransplantation from open-ended engineering toward a defined transgene recipe for durable organ supply (Nature Communications; eGenesis-supported).

[DD+TCR] Talos automated genomic reanalysis workflow (Microsoft Research/Centre for Population Genomics/Broad Institute) recovered 90% of known diagnoses in validation and surfaced 241 new rare-disease diagnoses across 4,735 previously undiagnosed patients, with an average 32-day lag between new supporting evidence and confirmed diagnosis; open-sourced on GitHub.

[DD+TCR] AI-guided framework reading high-resolution cell atlases and language models identified GPNMB as a versatile multi-cancer CAR-T antigen with potent xenograft activity; AI-CURA automated LLM workflow classified genetic variants at high accuracy, removing a bottleneck that once constrained entire diagnostic labs.

[DD+POD] Pragmatic cluster-randomized trial across 16 Penda Health facilities in Kenya (9,691 patients, 103 clinical officers) found ChatGPT-4o decision support produced no significant reduction in 14-day treatment failure (2.2% vs. 2.0%): a well-powered null result reported without spin, documenting where the capability does not yet move the primary-care outcome.

[SCAN+TCR] Re-dosed AAV-hOTOF gene therapy restored hearing in four deaf children past pre-existing neutralizing antibodies in a second ear, lifting average thresholds from over 95 dB to 43 dB: first demonstration that re-dosing clears the antibody barrier previously limiting cochlear gene therapy to single-treatment protocols.

[DD+POD] UC Berkeley AI trained on hundreds of thousands of EKGs predicted sudden-cardiac-death risk far better than existing clinical methods, reading danger in traces clinicians rated as unremarkable, from a test available in any clinic, extending the June 22 AI-ECG transplant finding into a second EKG-as-prognosis result.

[DD+POD] Nature Medicine plasma profiling of 1,714 patients across five tumor types and 16 cohorts identified a histidine metabolite signature predicting immunotherapy survival; histidine supplementation then improved progression-free survival in patients without the gut-microbiome signatures that catabolize it: prognostic marker and dietary intervention delivered in the same research arc.

[SCAN+TCR] Phase 1 Lancet study demonstrated MRI can non-invasively deflate fetal tracheal occlusion balloons in utero for congenital diaphragmatic hernia, collapsing a two-intrauterine-procedure intervention into one without a second surgery.

[SCAN+TCR] AI-ECG algorithm detected occult structural heart disease missed on clinical examination, directly leading to a patient receiving a heart transplant; published in Nature.

[DD+POD] A multimodal framework (DeepSeek-R1 for parameter interpretation + MiniCPM-V for image recognition, both open weights) drives super-resolution ultrasound by voice command (acquisition, adaptive microbubble filtration, reconstruction, and a structured diagnostic report in ~4 minutes), validated in a 14-clinician evaluation published in npj Digital Medicine, registered in the Chinese Clinical Trial Registry.

[DD+POD] John Jumper (2024 Nobel Chemistry co-laureate, AlphaFold co-creator behind 200M+ open protein structure predictions) joined Anthropic, signaling that AI-for-science frontier capability is portable across institutional lines and that the next biological-domain compression may emerge from a lab other than the one that produced the breakthrough.

[DD+POD] BCI population more than doubled to ~150 people in roughly two years; Paradromics completed the first surgical implantation in the FDA-approved Connect-One Early Feasibility Study to restore speech at University of Michigan; China granted the first national BCI regulatory approval for use outside clinical trials, marking the transition from isolated demonstrations to a clinical field.

[DD+TCR] Royal Botanic Gardens Kew report: AI identifies the hardest plant specimens (sedges, peat mosses) faster than human specialists; AI analysis of 8 million digitized specimens documents flowering shifted 2.5 days/decade over the last century; high-quality genomes extracted from fungal specimens up to 180 years old: taxonomy and biodiversity genomics timeline compression documented at collection scale.

[DD+POD] Casey Harrell, paralyzed by ALS, has logged more than 3,800 independent hours at home over 22.6 months with a speech brain-computer interface at 99% accuracy and a vocabulary grown from 50 words to 125,000 (including patient-requested privacy mode and profanity filter), marking the transition of speech neuroprosthetics from clinical research demonstration to an independently used daily faculty (Nature Medicine).

[SCAN+TCR] Gait-synchronized deep brain stimulation that decodes a Parkinson's patient's step phase and times each pulse to footfall reduced falls versus continuous stimulation across two Nature Medicine studies.

[DD+POD] Lipid-nanoparticle platform achieved 49% in-vivo prime editing in mouse liver from a single 2 mg/kg dose; corrected PKU R408W mutation to anticipated-curative phenylalanine levels with fewer off-target edits than DNA delivery and only transient liver-enzyme elevation; redosable synthetic carrier enables repeat dosing, crossing the delivery bottleneck that confined prime editing to viral one-shot approaches (Nature Nanotechnology).

[SCAN+TCR] AstraZeneca's Truqap (capivasertib) received FDA approval as the first targeted therapy for PTEN-deficient prostate cancer, a poor-prognosis subgroup previously without a precision option.

[DD+TCR] Biohub/UC Berkeley laser phase plate cryo-EM converts phase shifts into visible contrast using laser light described as 100 million times brighter than the Sun, lifting atomic-scale imaging of proteins inside intact living cells from under 1% toward a projected 50%+ of the proteome, shifting structural biology from purified isolated proteins to native cellular environments where disease mechanisms actually occur.

[SCAN+TCR] General-purpose AI models outperformed specialized clinical systems across medical knowledge, clinician alignment, and real physician queries in a Nature Medicine study.

[DD+POD] Life Biosciences dosed the first human with an in-vivo partial cellular-reprogramming therapy: three Yamanaka-factor genes switched on in a glaucoma patient's optic-nerve neurons to coax aged cells toward a younger state without erasing their specialized identity.

[DD+TCR] BBM-P002 dual-enzyme Parkinson's gene therapy (AAVT42 vector co-delivering tyrosine hydroxylase + AADC) cleared a 12-month phase 1 safety read in 10 patients targeting autonomous dopamine synthesis without ongoing oral levodopa dependence.

[DD+TCR] ElHyX stretchable elastomer-hydrogel implant ran closed-loop glucose sensing and neuromodulation in diabetic rats while maintaining electrical performance under body-motion strain without sutures: preclinical proof of continuous sense-and-treat tissue integration.

[DD+POD] David Sinclair confirmed plans to administer oral epigenetic-reprogramming compound SL-100 in first human trials via $101M XPrize Healthspan competition requiring measurable 10-year age reversal within one year; 65 teams narrowing to 10 finalists all entering human trials in 2026.

[SCAN+TCR] Whole-exome analysis of DECLARE-TIMI 58 found dapagliflozin cut heart-failure hospitalization at hazard ratio 0.18 in cardiomyopathy gene variant carriers vs. 0.73 in noncarriers (Nature Medicine): first genetically stratified readout pointing toward prevention before disease appears.

[SCAN+TCR] Neuronoff implanted first patient with needle-placed Injectrode electrode for neurogenic bladder in spinal cord injury under a DOD-funded trial, moving proven tibial-nerve stimulation from operating room to outpatient and at-home placement.

[DD+TCR] Retatrutide TRIUMPH-1 secondary readouts: knee osteoarthritis pain −73%, sleep apnea severity −61% atop 28.3% weight loss; TRANSCEND-T2D-1: A1C −2.0% with 90% reaching <7.0%: triple agonist reaching four conditions simultaneously from a single mechanism.

[DD+TCR] Aleniglipron Phase 2b ACCESS trial (n=230, Nature): oral GLP-1 achieved 11.3% placebo-adjusted weight loss at 36 weeks with no plateau and declining GI side effects: oral small-molecule matching injectable efficacy trajectory without injection or refrigeration.

[DD+TCR] Pfizer/Metsera berobenatide VESPER-3: monthly injectable sustained up to 12.1% weight loss to 28 weeks with no plateau: first evidence a monthly dosing interval holds efficacy comparable to weekly formulations at equivalent timepoints.

[DD+POD] DIOSynVax/Cambridge pEVAC-PS needle-free DNA vaccine, ML-designed super-antigen targeting conserved Sarbeco coronavirus features, cleared Phase 1 safety and immunogenicity in 39 volunteers with cross-reactive responses against SARS-CoV-2, original SARS, and bat coronaviruses; first AI-designed vaccine component validated in human testing.

[ARC] Otsuka's Voyxact slowed kidney-function decline in a Phase 3 IgA nephropathy readout: targeted-therapy result in a disease category with historically limited options.

[ARC] Multiplexed twin prime editing simultaneously knocked out up to 10 genes in crop plants in a single operation: first demonstration at that scale in agricultural plant genomes.

[DD+POD] Cervical epidural spinal cord stimulation immediately restored arm strength (avg. 32% gain, no serious adverse events) in 7 chronic post-stroke patients with only 8.6 hours of motor activity: Nature Medicine feasibility trial opening a disability category medicine had treated as permanently closed to electrical addressability.

[DD+POD] Allen Institute launches $400M Brain Health accelerator targeting Alzheimer's, Parkinson's, ALS, Huntington's, and Lewy body dementia with genetic therapies; funded by Allen Institute ($200M), Bezos family ($100M), NIH/AWS/EverythingALS ($100M): map-to-intervention transition for brain disease at accelerator scale.

[DD+TCR] Microsoft and Mayo Clinic announce partnership to build a frontier healthcare AI model owned by Mayo and trained on its de-identified clinical data, deploying internally before Azure Foundry API availability: institutional data-owner retaining model ownership rather than licensing from a platform.

[DD+TCR] Alnylam and Inceptive form $2B RNAi discovery collaboration pairing Alnylam's two decades of therapeutic RNA data with Inceptive's RNA foundation models for accelerated target-to-candidate discovery.

[DD] Nature Biotechnology: single-cell spatial pharmacobiology maps periostin-rich ECM and cancer-associated fibroblast neighborhoods blocking antibody delivery in head/neck and pancreatic tumors: first intratumor pharmacokinetic map explaining why EGFR-targeting drugs fail inside solid tumors.

[DD+POD] Johns Hopkins identifies brain region governing the shift from deliberate action to automatic behavior, with habits forming faster than previously thought: neural circuit basis for behavioral change becoming directly visible.

[SCAN] Edwards Lifesciences receives FDA approval for Triformis Resilia, the first surgical valve designed specifically for tricuspid valve disease: previously neglected cardiac anatomy reaching purpose-built intervention.

[SCAN] Zepto Life Technology receives FDA Breakthrough Device Designation for FungiFlex Mold Panel plasma liquid biopsy detecting invasive mold pathogens including Aspergillus and Mucorales from cell-free DNA.

[ARC] Savolitinib posted a positive Phase 2 result in MET-amplified gastric adenocarcinoma: a confirmed biomarker-targeted response in a historically poor-prognosis GI cancer, extending the targeted-oncology wave documented across ASCO 2026.

[DD+POD] MIT/USC/Harvard/UCLA postage-stamp ultrasound sticker corrected arrhythmias noninvasively in rats and engineered human cardiac cells via sonogenetics: focused ultrasound plus one-time gene therapy; no surgery required.

[SCAN+TCR] King's College London "Efflux Resistance Breaker" antibiotic design strategy overcame efflux-mediated drug resistance in preclinical tests, opening a structural pathway to reviving retired antibiotics.

[ARC] Medically tailored meals cut hospitalizations and healthcare costs in Massachusetts Medicaid per dual Nature Medicine studies, validating food-as-medicine intervention at healthcare-system scale.

[DD+POD] SMArT AND-gate transient transactivator system enriched CRISPR-HDR-edited human hematopoietic stem cells to 80 to 100% purity while depleting genotoxic off-target rearrangements, validated in mouse xenotransplant: removes the HDR efficiency bottleneck holding precise somatic gene correction behind disruption-style editing for a decade.

[SCAN+TCR] Self-inserting DNA-origami nanopore tiles achieved stable intracellular voltage recordings and drug delivery in live neurons including thin dendrites without membrane rupture: new access route for neural interfaces previously blocked by cell fragility.

[ARC] ASCO 2026 readouts: ivonescimab cut first-line NSCLC death risk 34% (HARMONI-6 trial); Lilly's Retevmo aced early-stage lung cancer; daraxonrasib confirmed as oral daily pill doubling pancreatic cancer median survival: three targeted-therapy advances landing at one conference slate.

[DD+POD] Amivantamab (J&J) eradicated tumors entirely in 15 of 102 head-and-neck cancer patients whose disease had resisted both chemotherapy and immunotherapy, across an 11-country trial; triple mechanism (EGFR + MET blockade + immune activation); subcutaneous delivery moves treatment out of infusion suites.

[DD+POD] Revolution Medicines began shipping daraxonrasib to physicians under an FDA early-access program ahead of formal approval: first patients now receiving the drug that nearly doubled median pancreatic cancer median survival in Phase 3 (covered April 14).

[SCAN+TCR] FDA granted Breakthrough Therapy designation to Merck's calderasib for first-line KRAS G12C metastatic NSCLC and approved Afrezza needle-free inhaled insulin for pediatric use in the same week: two targeted-therapy category firsts in a single news cycle.

[ARC] DARPA funding shelf-stable synthetic blood substitutes toward FDA approval by 2029: military-accelerated pathway compressing a product with no civilian manufacturing precedent toward regulatory clearance on a compressed timeline.

Scribe Therapeutics' STX-1150 CRISPR-CasX epigenetic PCSK9 silencer sustained >50% LDL reduction for 22+ months from a single dose in non-human primates without altering DNA; Phase 1 enrollment begun in Australia: durable single-dose cardiovascular prevention without ongoing adherence or permanent genome modification.

*Nature Medicine* Phase 2 trial of rogaratinib produced clinical responses in SDH-deficient gastrointestinal stromal tumors: first epigenetically-driven cancer category reached by a tyrosine kinase inhibitor already on pharmacy shelves, reframing epigenetic mechanism as actionable downstream target class rather than separate undruggable problem.

Chan Zuckerberg Biohub's open-weight ESMFold2 and ESM Atlas enable wet-lab researchers to design functional protein binders against novel targets in under 72 hours on consumer hardware: discovery-loop access that was concentrated in ~20 institutions now available to several thousand.

Wearable ultrasound patch autonomously tracked fetal blood-flow spectra across 52 high-risk pregnancies in Nature Biotechnology, agreeing with handheld clinical instruments without a sonographer present: autonomous specialist-grade fetal monitoring demonstrated at bedside scale.

ASCO 2026 late-breaker slate features pivotal Phase 3 readouts across seven cancer types: pancreatic (daraxonrasib), prostate (PROTEUS, TALAPRO-3), bladder, hepatocellular, multiple myeloma (mezigdomide), uveal melanoma (darovasertib); several targeting diseases treated as therapeutically closed for decades; Topol synthesis documents exponential proliferation of immunotherapy modalities reaching readout phase simultaneously.

FDA approved Gilead's Hepcludex as the first antiviral treatment for chronic hepatitis D, the most severe form of viral hepatitis, ending decades with no approved option.

ScienceDaily: semaglutide (Wegovy) shown to target arthritis inflammation: GLP-1 mechanism expanding from metabolic and mood domains to musculoskeletal disease, the third distinct biological system the drug class has been confirmed to affect.

Eli Lilly's triple-agonist retatrutide posted 28.3% average weight loss in Phase 3: highest figure recorded for any GLP-class molecule in late-stage trials, continuing semaglutide (mid-teens) → tirzepatide (~20%) → retatrutide trajectory; additional tri- and quad-agonist candidates already in earlier-stage trials.

FDA cleared Sunrise's rechargeable mandibular sensor for multi-night at-home sleep apnea definitive diagnosis, collapsing a billion-person diagnostic bottleneck from wired sleep-lab visits costing thousands of dollars to bedside testing.

Nature feature documents representational drift: individual neurons reshuffle which memories they encode over days and weeks while the memories themselves hold stable, reframing cognition's substrate as dynamically fluid rather than fixed, with direct implications for BCI decoder design, memory-disorder models, and continual-learning AI architectures.

SandboxAQ integrated physics-grounded quantum chemistry and molecular dynamics models into Claude, making drug-discovery simulations (Schrödinger's equation, reaction microkinetics) accessible via conversational interface without specialized computing infrastructure.

IBEC/West China Hospital nanoparticle therapy restores LRP1 blood-brain barrier transport, drops brain amyloid-β 50-60% within one hour and reverses cognitive pathology in 12-month-old mice six months post-treatment (Signal Transduction and Targeted Therapy): distinct mechanism from plaque-attack antibodies Cochrane review closed out.

Queen Mary/Norwegian School 7-day fasting proteomics mapped ~3,000 blood proteins across 12 volunteers, pinpointing major molecular reorganization beginning after day three concentrated in extracellular matrix structures, published in Nature Metabolism: maps which pathways fasting activates for pharmacological targeting.

OHSU team identified a small-molecule compound disabling MYC's hidden DNA-repair function selectively in cancer cells without disrupting normal tissue (Genes & Development): opens a 40-year-treated-as-undruggable target by resolving that the protein was running separable biochemical jobs, not a single undifferentiated function.

WHO declared PHEIC over Bundibugyo ebolavirus crossing DRC-Uganda border (8 confirmed, 246 suspected) without convening its emergency committee; no licensed vaccines or therapeutics exist for this species; trial protocols for cross-species candidates pre-drafted and waiting on an active-outbreak regulatory trigger.

Spinach-derived chloroplasts transplanted into mouse retinal photoreceptors produced ATP and NADPH inside living mammalian cells for several days (Cell): first cross-kingdom organelle function demonstrated in mammalian tissue.

University of Würzburg (Nature Cell Biology) identified vitamin B2 as the cofactor enabling FSP1 to protect cancer cells from ferroptosis; bacterial analog roseoflavin triggered cell death across multiple tumor lines: mechanism and candidate molecule delivered in a single research arc.

Ensitrelvir Phase III (NEJM): 2.9% vs. ~9% symptomatic COVID in ~2,000 household contacts randomized within 72 hours of exposure: first rigorous post-exposure prophylaxis proof-of-concept for COVID; FDA decision expected June.

Mayo Clinic DNA aptamers bind selectively to senescent cells in human tissue and live animal models: first reliable readout for senolytics field, enabling measurable dosing protocols, trial endpoints, and next-generation therapy design.

Blood-borne CD8+ T-cells identified as new cognitive aging lever; blocking their migration into the aging brain reversed memory deficits in aged mice: parallel pathway to amyloid/tau, expanding dementia intervention surface.

Nature: 427,000-cell atlas of 119 triple-negative breast cancer patients identifies four tumor ecotypes predicting neoadjuvant chemotherapy response, outperforming every prior TNBC biomarker and enabling patient stratification before treatment begins.

Nature: tooth enamel proteins from six Chinese Homo erectus specimens document AMBN(M273V) variant shared with Denisovans, placing a previously unknown super-archaic introgression event deep in the human family tree and reframing human emergence as networked rather than branching.

Nature: ZFP384 identified as transcriptional switch controlling microglial reparative duration after ischemic stroke; antisense oligonucleotides sustaining reparative phase produced measurable functional recovery weeks post-acute, opening the chronic stroke phase to pharmacological intervention.

HHMI Janelia Research Campus and Baker lab at University of Washington released NovoTags, library of AI-designed fluorescent proteins generated by RFdiffusion-class model that expand multi-color live-cell imaging palette beyond natural protein repertoire; designs and protocols released publicly.

Iowa State team led by Yang Yang captured SARS-CoV-2 proofreading enzyme (exoribonuclease) interacting with antiviral nucleotide analogs at 2.4-angstrom resolution (Nature Communications, PNAS): opens two new antiviral design pathways against the proofreading function that has limited remdesivir efficacy since 2020.

Nature Communications publishes one-year deployment of decentralized nanopore sequencing for Plasmodium falciparum across six sub-Saharan African countries: 1,065 samples sequenced locally at under $25/sample with ~5-hour turnaround on offline-laptop dashboards, covering drug-resistance genes, hrp2/hrp3 deletions, and vaccine target csp.

Transplanting gut microbiota from young mice into middle-aged mice reversed multiple liver-aging signatures including reduced cellular senescence and fibrosis, and suppressed MDM2 expression: microbial communities re-exporting youth-associated signaling into aged tissue and quieting a canonical cancer-surveillance gene.

Wake Forest, Duke, and Wisconsin labs jointly publish in PNAS that SP6/SP8 genes activate during regeneration in axolotls, zebrafish, and mice; CRISPR knockout of SP8 disabled axolotl bone rebuilding; viral gene therapy modeled on zebrafish regeneration enhancer carrying FGF8 partly restored mouse digit-bone regrowth.

Project CETI's autonomous SeaExplorer glider separated 7 distinct sperm whale voices from 37 echolocation clicks in single 3-second window off Dominica; in French sea trials steered toward played whale clicks within 2.6-4.6 minutes during dives to 50/100/150m, published in Scientific Reports.

Shamir Myopia Control lens 24-month RCT (126 Israeli children, ages 6-13) shows 33% slower axial length elongation and 26% slower spherical equivalent progression vs single-vision spectacles; effect rises to 44%/43% in children under 10; daily wear time 14.7h matched controls.

Dana-Farber team led by Brian Wolpin reported in NEJM that an investigational drug targeting a family of mutant KRAS variants extended survival in pancreatic cancer patients, breaking a 40-year "undruggable" assumption that locked pancreatic oncology out of targeted therapy.

University of Minnesota team (Elias/Sikdar) in npj Biofilms and Microbiomes used lactonase enzymes to interrupt bacterial quorum-sensing signals in dental plaque, shifting oral microbiomes toward health-associated species without killing bacteria; framed as proof of concept extensible to IBD, autoimmune, and metabolic dysbiosis.

Moderna’s mRNA flu vaccine beat standard shots by 27% in a 40,000-person NEJM Phase 3 trial across 11 countries, with FDA decision expected Aug. 5.

Harvard/Beth Israel study of 76 ER cases found OpenAI o1 gave exact or very close triage diagnoses 67% of the time vs. 50-55% for two attending physicians; Cochrane review of 17 anti-amyloid Alzheimer’s trials covering 20,342 participants found no clinically meaningful benefit and higher brain-swelling/bleeding risk.

Stellenbosch University researchers found the first evidence of flavoalkaloids in cannabis leaves, identifying 25 previously unknown phenolic compounds among 79 detected.

Friedrich Miescher Institute researchers built an endometrial organoid that completed a full menstrual cycle in vitro, identifying surface luminal cells as drivers of scarless tissue regeneration.

Mayo Clinic published a *Gut* AI model detecting pancreatic cancer in CT scans up to three years before diagnosis, finding prediagnostic cases at nearly double specialists’ unaided rate.

Intellia’s Phase 3 in-vivo CRISPR therapy lonvoguran ziclumeran cut hereditary angioedema attacks 87% vs. placebo, with 62% attack-free six months after one infusion.

Isomorphic Labs said it will begin human trials of AI-designed oncology and immunology drugs, while FDA approved Regeneron’s Otarmeni as the first gene therapy for genetic hearing loss and the company said it will provide it free to eligible U.S. patients.

University of Lausanne identified vitamin B7/biotin deprivation as a cancer metabolic chokepoint, showing tumors need biotin-dependent pyruvate carboxylase to bypass glutamine addiction.

Nature reported ThermoCas9, a CRISPR variant that reads DNA methylation to selectively cut tumor DNA while sparing healthy cells; a Science Translational Medicine study showed methionine/arginine/serine supplementation boosted mRNA delivery up to 20x and single-dose CRISPR editing from ~25% to nearly 90%.

Rice University’s Sequence Display platform generated 10M+ protein activity data points in one experiment and compressed protein-engineering cycles from months to three days.

Northwestern printed graphene/molybdenum-disulfide artificial neurons that triggered living mouse brain cells, and a Pittsburgh *Nature Communications* trial showed donor regulatory dendritic cells let 3 of 13 liver transplant recipients stop immunosuppressants for 3+ years.

OpenAI released GPT-Rosalind, its first life-sciences model for evidence synthesis, hypothesis generation, and experimental planning, via trusted access with Amgen, Moderna, Allen Institute, and Thermo Fisher Scientific.

University of Oklahoma identified FGF21 reversing obesity in mice via a hindbrain circuit overlapping GLP-1 targets but increasing energy burn rather than suppressing appetite; UCLA cleared senescent p21+TREM2+ macrophages to reverse fatty liver in mice, with the same signature confirmed in human biopsies.

Revolution Medicines' Phase 3 pancreatic cancer trial showed daraxonrasib cut death risk 60% and extended median survival to 13.2 months vs. 6.7 months on chemotherapy.

Stanford's Peptide Predictor algorithm scanned all 20,000 human protein-coding genes, identified 2,683 candidate peptides from 373 prohormones, and surfaced BRP: a BRINP2-derived peptide activating hypothalamic appetite neurons 10x more strongly than GLP-1, producing 3g fat-only weight loss in obese mice with no gastrointestinal side effects; company formed to begin human trials.

Stanford/ETH Zurich identify ~10% of population carries PAM enzyme gene variants producing GLP-1 resistance: higher circulating GLP-1 but reduced biological activity, confirmed across human studies, mouse models, and clinical trial data after decade of verification.

Weizmann Institute (*Science*) finds genetics account for ~50% of human lifespan variation (at least double prior consensus) after filtering extrinsic deaths using Swedish/Danish twin databases including twins raised apart; dementia heritability up to age 80 found to be ~70%.

Allogene Therapeutics off-the-shelf CAR-T therapy achieved 58% minimal residual disease negativity in lymphoma vs. 16% with standard care in ongoing Phase 3 trial: capability transfer of cancer immunotherapy to off-the-shelf allogeneic platform documented at Phase 3 scale.

Zilebesiran twice-yearly blood pressure injection documented: ultra-long-acting antihypertensive dosing interval representing structural departure from daily oral regimen architecture.

UC Riverside chemists stabilized a carbene in liquid water for the first time, confirming a 67-year-old Breslow hypothesis about vitamin B1 and opening pharmaceutical synthesis in water rather than toxic organic solvents; DZNE/LMU identified phosphatidylserine "eat-me" signal causing microglia to destroy olfactory-locus coeruleus nerve fibers years before Alzheimer's cognitive symptoms, validated across mouse models, patient tissue, and living PET scans; CorTec received FDA Breakthrough Device Designation for brain-computer interface in stroke rehabilitation; HIV/Ebola nanodisc vulnerability mapping published.

University of Chicago identifies zeaxanthin (common plant nutrient in spinach and peppers) as direct enhancer of cancer-fighting T cells improving immunotherapy outcomes in animal studies.

New research suggests Alzheimer's treatment paradigm may require fundamental revision per ScienceDaily coverage; perovskite solar cell performance linked to structural defects (new mechanistic finding); superconducting halo discovered in UTe2.

German team reports CAR-T cell therapy eliminated all symptoms of three simultaneous autoimmune diseases in a patient who had failed nine prior treatments; symptom-free and medication-free fourteen months later: capability transfer of cancer therapeutic paradigm to autoimmune disease.

UCSF (Nature Aging) identifies FTL1 as single protein driving hippocampal aging in mice; reducing FTL1 in older mice rebuilt neural connections and reversed memory decline; McMaster (Neuron) identifies hidden brain cells driving cancer growth; Birmingham study finds gut signals detectable as early cancer markers.

Zhejiang University (Nature Communications) finds training AI vision models on human brain signals improved abstract concept recognition 20.5%, outperforming models with 14x more parameters: biological neural architecture as structural guidance outperforming parameter scaling.

Anthropic acquires Coefficient Bio ($400M stock deal), 10-person drug discovery team from Genentech's Prescient Design, integrating into health and life sciences division: frontier AI company acquiring domain-specific biological discovery capability directly.

Karolinska Institutet (Nature Medicine): single cochlear OTOF gene therapy injection restored hearing in all 10 patients including teenagers and adults, average threshold improving from 106 dB to 52 dB within six months; researchers extending approach to GJB2 and TMC1 genes.

Two independent analyses (Oratomic/Caltech + Google) find P-256 elliptic curve encryption crackable with ~10,000 qubits, compressing quantum cryptographic threat from "decade away" to potentially before 2030; Cloudflare cites "renewed urgency."

FDA approves Eli Lilly's oral GLP-1 pill Foundayo for obesity; available next week at $149-$349/month ($25 with coupon); Novo Nordisk's competing pill reported 600,000+ prescriptions in March, expanding market rather than cannibalizing injectables.

KAIST develops self-regenerating catalyst system (silver + organic photocatalyst) synthesizing pharmaceutical-grade amines using only sunlight and atmospheric oxygen, with reaction byproducts automatically regenerating the catalyst: closed-loop pharmaceutical synthesis from ambient energy inputs demonstrated, published in JACS.

Eli Lilly signs $2.75B deal ($115M upfront) with Insilico Medicine for 28 AI-generated drug compounds, nearly half already in clinical stages: AI-native discovery pipeline priced as production-grade pharmaceutical input by top-5 pharma company.

Study of ~96,000 people finds 15-20 minutes/week of vigorous activity associated with 63% lower dementia risk, 60% lower type 2 diabetes risk, and 46% lower mortality risk.

Penn researchers develop AI-guided gene therapy silencing chronic pain by targeting specific brain circuits, reproducing morphine's analgesia without activating addiction reward pathways: preclinical proof-of-concept.

NYU identifies split-signal protein system in brown fat where two fragments of a single molecule independently guide blood vessel and nerve network growth: new obesity treatment pathway via energy expenditure rather than appetite suppression.

New U.S. cholesterol guidelines shift to earlier, personalized prevention; erythritol linked to brain blood vessel disruption and stroke risk; gut-brain appetite suppression pathway identified.

Carlos Simon Foundation (Valencia) keeps donated human uterus alive outside the body for 24 hours using PUPER machine perfusion device mimicking cardiovascular system: first such demonstration; opens study of embryo implantation, uterine disorders, and potentially full ex-vivo gestation.

Baylor College of Medicine (Science Advances) identifies brain pathway through which metformin suppresses hypothalamic Rap1 protein and lowers blood sugar at doses thousands of times lower than oral treatment: 60-year-old drug reveals hidden neural metabolic regulation mechanism with implications for neurodegenerative disease.

Kumamoto University develops cyclic peptide platform delivering oral insulin at 33-41% bioavailability vs. injection, published in Molecular Pharmaceutics: molecular barrier confining insulin to needles crossed.

Earendil Labs raises $787M backed by Sanofi and Pfizer for AI biologics platform generating 40+ drug programs; Sanofi committed ~$4.5B across three deals in under 12 months; anti-TL1A antibody HXN-1001 entering Phase 2.

Heidelberg University identifies NMDAR/TRPM4 "death complex" as downstream Alzheimer's neuronal death mechanism distinct from amyloid; compound FP802 disrupts interaction, preserved memory and reduced amyloid in mice (Molecular Psychiatry).

NIH-supported researchers develop four-marker blood test detecting pancreatic cancer in >90% of cases including 87.5% of early-stage tumors.

Large Lancet Psychiatry study finds semaglutide (Ozempic) associated with 42% fewer psychiatric hospital visits, 44% lower depression risk, and 47% lower substance use disorders during treatment: GLP-1 mechanism crossing metabolic, mood, and addiction domains simultaneously.

New experimental drug shrinks tumors in prostate cancer clinical trial (ScienceAlert): targeted cancer therapy milestone.

Phase III trial of oral PCSK9 inhibitor enlicitide (2,909 patients, NEJM) achieves 60% LDL reduction matching injectable therapies: first oral pill to match injectable efficacy, removing primary adoption barrier for population-scale cardiovascular prevention.

University of Geneva MangroveGS AI system predicts cancer metastasis risk at ~80% accuracy across colon, stomach, lung, and breast tumors from gene expression patterns in hospital tumor samples: cross-tumor generalization from single training context.

Scientists engineer probiotic bacteria into tumor-hunting cancer killers (PLOS Biology); Harvard engineers build chip that twists and controls light in real time (Optica); 48-dimensional quantum light structure discovered (Nature Communications).

Mass General Brigham/Dana-Farber Phase 1 trial (Cell): engineered herpes virus injected into glioblastoma recruits and activates T cells deep inside tumor; spatial proximity of T cells to dying tumor cells correlates with longer survival in 41-patient trial: first demonstration converting glioblastoma from immunologically cold tumor to active immune battlefield.

ScienceDaily: gum disease bacterium (Fusobacterium nucleatum) linked to breast cancer growth and spread (Cell Communication and Signaling); ETH Zurich develops single-atom catalyst converting CO2 directly into fuel; shingles vaccine found to cut heart risk nearly in half (American College of Cardiology).

FDA grants Breakthrough Device Designation to Nia Therapeutics' 60-channel AI-guided brain implant that decodes memory states in real time and delivers targeted stimulation; 19% recall improvement in randomized trial; first designation for TBI memory loss treatment.

Guangzhou Medical University (Cell): red blood cell membrane disguise enables mitochondrial transplant at ~80% delivery efficiency vs. prior <5%; extended survival ~20% in Leigh syndrome mice: delivery barrier that constrained mitochondrial therapy for decades crossed.

Northwestern surgeons kept patient alive 48 hours without lungs on artificial system; molecular analysis provided first biological proof that some acute respiratory failure is irreversible, opening bridge-to-transplant pathway for previously unrecognized fatal cases (Cell Press/Med).

Berkeley Lab simulated quantum chip in extreme detail using 7,000 GPUs: computational quantum simulation threshold documented.

AlphaFold database adds 1.7 million homodimer predictions from 20 species including humans and M. tuberculosis: first extension from isolated proteins to functional complexes, closing the gap between computational structure prediction and biological reality.

VIB/KU Leuven (Nature Neuroscience): lecanemab's Fc fragment identified as essential mechanism reprogramming microglia to clear amyloid plaques; SPP1 gene expression pattern documented; Fc removal abolishes efficacy: opens direct microglial activation as antibody-free therapeutic strategy.

Harvard Wyss Institute (Nature Biomedical Engineering): DoriVac DNA origami vaccine platform matches mRNA immune activation in human organ-on-chip models while offering improved stability and manufacturing; designed for peptide regions conserved across SARS-CoV-2, HIV, and Ebola.

Washington University (PNAS): clusters of epithelial cells collectively sense physical features up to 100 microns away (10x individual cell range) by pulling on collagen matrix; cancer cells exploit enhanced collective sensing to navigate tissue; two-stage coordination mechanism identified.

MIT (Nature Communications): gut protein identified that traps and kills dangerous bacteria through previously uncharacterized mechanism.

Houston Methodist (Nucleic Acids Research): TDP43 protein identified as regulator of DNA mismatch repair; abnormal levels cause hyperactive repair machinery that damages neurons and correlates with higher tumor mutation loads: first mechanism bridging ALS/dementia and cancer through a single pathway.

University of Barcelona: FLAV-27 epigenetic drug (G9a inhibitor) reverses cognitive decline in multiple Alzheimer's animal models by reprogramming neuronal gene expression rather than clearing amyloid plaques: first-in-class approach distinct from lecanemab/donanemab mechanism.

UC Santa Cruz (Journal of the Endocrine Society): fathers' tobacco use linked to metabolic changes in their children: paternal epigenetic transmission documented in humans, extending multigenerational biology arc.

Cold Spring Harbor Laboratory (Science): Conservatory tool identifies 2.3 million regulatory DNA sequences conserved across 314 plant genomes for 400+ million years; three organizational principles documented; atlas covers dozens of crop species and wild ancestors: opens regulatory DNA as precision engineering target for drought/disease/yield traits.

University of Turku (Nature Communications): breakthrough in production of vital chemotherapy agent; University of Gothenburg (Cell Reports): gut bacteria producing serotonin identified as key to IBS; Queen Mary/L'Oréal (Nature Communications): textbook model of human hair growth corrected.

Nine of xAI's twelve cofounders have departed; Musk acknowledges company "was not built right" and orders rebuild "from the foundations up"; Grok coding product critically behind Claude Code and OpenAI Codex; SpaceX/Tesla managers auditing and firing staff: organizational failure pattern documented alongside Meta Avocado delay as capital-cannot-purchase-research-culture signal.

University of Geneva (Nature Metabolism): D-cysteine mirror amino acid enters cancer cells via tumor-specific transporter, blocks mitochondrial NFS1 enzyme, slows aggressive tumor growth in mice without harming healthy tissue: selectivity derived from molecular asymmetry rather than genetic or chemical targeting.

Trinity College Dublin (PNAS): analysis of 2,500+ thermal performance curves across thousands of species confirms universal curve shape governing temperature response in all life from bacteria to reptiles: shape immutable across billions of years of evolution, only position on temperature axis shifts; narrows assumed evolutionary flexibility for climate adaptation.

~1,000 researchers publish Humanity's Last Exam: 2,500-question benchmark engineered by removing any question solvable by current AI; GPT-4o scores 2.7%, Claude 3.5 Sonnet 4.1%, most capable systems (Gemini 3.1 Pro, Claude Opus 4.6) reach 40 to 50%: documents remaining frontier gap while trajectory suggests rapid closure.

Scripps Research (Nature Aging): structural changes in three blood proteins (C1QA, clusterin, apolipoprotein B) classify Alzheimer's status at 83% overall accuracy and >93% in pairwise comparison: protein folding pattern rather than concentration as diagnostic signal; validated across independent cohorts and repeat testing.

University of Queensland (Translational Psychiatry): brain and blood cells in young adults with depression overproduce ATP at rest but cannot increase output under stress: inverts assumption of low energy production; opens mitochondrial reserve capacity as early-intervention diagnostic target.

Leiden University (Nature Communications): new antibiotic stops C. difficile gut infection without destroying microbiome: selective pathogen targeting preserving commensal bacteria.

Boyce Thompson Institute/Cornell/Edinburgh (Science): RbcS-STAR protein in hornworts causes Rubisco to cluster into dense compartments; mechanism functions when transferred to Arabidopsis and when STAR tail alone is grafted onto native Rubisco: modular, cross-species tool for engineering carbon-concentrating photosynthesis into crops.

University of Gothenburg (The Lancet): pill identified as potential treatment for sleep apnea.

Center for Genomic Regulation (Nature Communications): 200+ metabolic enzymes found physically attached to DNA inside cell nuclei with tissue/cancer-specific fingerprints: overturns compartmentalized model of metabolism and genome regulation; IMPDH2 shows location-dependent function; distinct patterns in breast vs. lung cancer confirmed in patient samples.

EPFL develops optovolution: light-pulse-guided protein evolution producing 19 variants with dynamic switching behaviors, including a protein functioning as a biological AND-gate logic gate activating only when two signals simultaneously present: biological computation demonstrated via directed evolution.

INSERM/Cell Press Blue: tanycytes identified as active tau-clearance shuttle from CSF to bloodstream; damaged tanycytes found in Alzheimer's patients: extracellular clearance pathway distinct from UCLA's intracellular CRL5SOCS4 mechanism documented March 4.

Researchers create psilocin derivatives activating serotonin pathways with significantly fewer hallucinogenic effects in mice (Journal of Medicinal Chemistry); ketamine mechanism for lifting severe depression imaged via brain scan (Molecular Psychiatry/Yokohama City University).

Hebrew University identifies molecular chain reaction (nitric oxide/mTOR pathway) that may drive some autism forms; pharmacological intervention restored normal cellular activity in experiments (Molecular Psychiatry).

Mayo Clinic identifies rare gene mutation causing fatty liver disease (Hepatology).

Cambridge/PNAS: golden retriever gene variants linked to anxiety, aggression, and intelligence traits with human analogs: cross-species behavioral genetics bridge.

Northwestern/PNAS: organized scientific fraud networks now publishing fake research faster than legitimate science appears; paper mills described as "essentially criminal organizations"; automated detection system deployed scanning for fabricated instrument identifications.

UCL/Science Translational Medicine: LRG1 protein identified as initiator of earliest diabetic retinopathy damage, upstream of VEGF; blocking LRG1 in diabetic mice prevented early retinal damage entirely; drug candidate in preclinical testing via Senya Therapeutics spinout.

Lund University/PNAS: cartilage scaffold enables body to regrow bone: tissue engineering advance in regenerative medicine.

Texas Children's Hospital/Science Translational Medicine: boosting key brain protein shows potential for treating Rett syndrome.

Hebrew University/British Journal of Pharmacology: CBD and CBG cannabinoids may help reverse fatty liver disease.

Johns Hopkins (Science Translational Medicine): AI-driven liquid biopsy detects silent liver fibrosis and cirrhosis from DNA fragmentation patterns in single blood draw, years before symptoms surface.

Salk Institute (Nature): molecular switch identified that revives exhausted cancer-fighting T cells.

Max Planck Institute (Nature Materials): hidden mechanical force identified that guides neural wiring during brain development.

Experimental drug cuts seizures up to 91% in children with Dravet syndrome by amplifying healthy gene copy protein production (UCL/GOSH, NEJM); Duke pyroelectric photodetector captures full electromagnetic spectrum in 125 picoseconds at room temperature using silver nanocube plasmonics: hundreds of times faster than existing thermal sensors; GLP-1 drugs show promise treating addiction (large BMJ study) and post-heart-attack recovery (Bristol/UCL, Nature Communications); AI detects acromegaly from hand photos (Kobe University, JCEM); Evo 2 infers complex eukaryotic genome architecture from raw sequence data without expert annotation.

UCLA/UCSF (Cell): CRISPR screen of lab-grown human neurons identifies CRL5SOCS4 protein complex that tags tau for destruction; neurons with higher complex levels survive Alzheimer's damage; mitochondrial stress linked to tau fragment matching blood biomarker: opens amplification of existing cleanup systems as therapeutic strategy.

University of Notre Dame (Nature Communications): analysis of 831 + 145 adults confirms intelligence emerges from distributed whole-brain network coordination, not localized regions; regulatory hubs orchestrate information flow; general intelligence depends on balancing local specialization with global integration.

Rice University produces first dye-free molecular atlas of Alzheimer's brain via hyperspectral Raman imaging + ML (ACS Applied Materials and Interfaces): chemical disruptions spread unevenly across whole brain, not localized to amyloid plaques; hippocampus and cortex show dramatic cholesterol and glycogen shifts: reframes Alzheimer's as whole-brain metabolic event.

Oregon State University (Advanced Functional Materials): iron-based metal-organic framework triggers dual oxidative attack (hydroxyl radicals + singlet oxygen) activated by tumor acidity and H₂O₂; complete tumor regression in mice, no recurrence, no systemic toxicity; healthy tissue unaffected: precision-activation via disease microenvironment chemistry.

University of Liège (Immunity): genetic switch identified that coordinates organ health maintenance; Roche plans oral BTK inhibitor (fenebrutinib) MS filing after Phase 3 clean sweep.

Rockefeller University maps ~7 million cells across 21 organs in mice, identifying ~1,000 shared genomic regulatory hotspots coordinating body-wide aging; aging onset documented at 5 months (earlier than assumed); 40% of changes sex-differentiated; single graduate student processed entire dataset.

Caltech (Nature): unrelated bacteriophages independently evolved proteins disabling MurJ cell-wall assembly protein via identical structural lock: convergent evolution identifies antibiotic target absent in human cells.

ETH Zurich trains neural network to map dynamic protein hydration shields via molecular dynamics + neutron scattering validation; could reduce biologic drug waste up to 30%; released as open-source software.

University of Bath (Nature Sustainability): engineered Pseudomonas putida converts stale bread into biodegradable PHA bioplastic at 500 kg/week pilot scale; BioLoaf Materials spin-off targeting commercial plant; UK discards 900,000 tonnes of bread annually.

UC Berkeley (PNAS): Methanosarcina acetivorans reads UAG codon as both stop signal and pyrrolysine-insertion instruction depending on cellular context: first documented natural genetic code ambiguity in a normally functioning organism; ~10% of inherited diseases (cystic fibrosis, Duchenne MD) caused by premature stop codons, suggesting therapeutic "leaky stop" approaches more feasible than assumed.

Scripps Research (Nature Structural & Molecular Biology): biomolecular condensates contain hidden internal protein filament scaffolds: overturns assumption they are structureless liquid droplets; scaffold required for function; opens condensates (previously considered undruggable) as therapeutic targets for ALS, cancer, and neurodegeneration.

MindRank doses first patient in Phase III trial of MDR-001, AI-designed oral GLP-1 receptor agonist for obesity/diabetes; reached Phase III in 4.5 years from project initiation vs. conventional decades-long timeline. Apheris launches ADMET Network: five pharma companies (Lundbeck, Orion, Recursion, Servier + one) pool 80% of proprietary ADMET data via federated learning to attack 40-45% clinical failure rate from absorption/toxicity prediction failures. Washington State University: single vinclozolin fungicide exposure in one rat generation produced epigenetic health effects amplifying across 20 generations: all 11 rats in one lineage had ovarian abnormalities by generation 20; 20-70% birth failures in later generations; disease severity increased rather than faded. NYU Langone: microplastics detected in 90% of prostate cancer tumors; cancerous tissue contains 2.5x more plastic (40 vs 16 micrograms/gram) than adjacent healthy tissue in same patients: first Western study with this design. Saarland University/PNAS: 3,000+ Paleolithic geometric signs on 260 artifacts (34,000 to 45,000 years old) display information density rivaling proto-cuneiform: pushes structured information encoding back 40,000 years before earliest known writing. Shingles vaccine may slow biological aging and reduce inflammation. Two-day oatmeal regimen cut LDL cholesterol 10%.

MIT/Broad Institute (Nature): mRNA-encoded thymic signaling factors delivered via lipid nanoparticles temporarily reprogram hepatocytes to produce T-cell maturation signals; restored T-cell diversity and vaccine/immunotherapy response in aged mice. MIT/Microsoft (Nature Communications): AI-designed peptide sensors tuned to cancer-linked proteases; nanoparticles cleaved by overactive proteases excrete reporter molecules in urine; ARPA-H collaboration targeting 30-cancer at-home screening kit. Saarland University/Tohoku University (Science): pentasilacyclopentadienide synthesized: first silicon-based aromatic molecule after ~50 years of attempts; independently replicated. University of Chicago (Nature Communications): tellurium-to-selenium ratio in ultra-thin films tunes material into topological superconducting state at up to 13K. USC/Alzheimer's & Dementia: silent drop in brain blood flow identified as potential early Alzheimer's marker. MIT (Advanced Materials): reformulated antibodies enabling subcutaneous injection instead of IV infusion. Nature: age of animal experiments waning as alternatives mature.

Korea Institute of Energy Research: fully automated robotic catalyst testing platform compressed 32 days of manual experiments into 17 hours (45x speedup, 32% less variability); patent filed; AI-driven design integration planned: advances closed-loop discovery cycle. University of Waterloo: engineered Clostridium sporogenes uses quorum sensing to activate oxygen-tolerance gene only after colonizing tumor interior; described as "genetic circuit" for biological computation inside cancer. FDA proposes "plausible mechanism" pathway for approving customized gene therapies tested in only a handful of patients; 60-day comment period opens. University of Waterloo/IBM Heron: encrypted quantum cloning demonstrated on 156-qubit processor: hundreds of encrypted qubit copies produced; enables fault-tolerant quantum cloud storage; published Physical Review Letters. BMJ study (63,433 UK adults): sugar restriction in first 1,000 days of life reduced cardiovascular disease risk 20-30% decades later.

Washington University/Nature Medicine: single blood draw measuring plasma p-tau217 predicts Alzheimer's symptom onset within ~3-4 years in cognitively normal adults; validated across multiple commercial platforms including one FDA-cleared; code made public. Osaka Metropolitan University/Scientific Reports: cleaner wrasse used external objects (food pieces) to probe mirror reflections: contingency testing previously documented only in dolphins and manta rays; suggests self-awareness more phylogenetically widespread than mirror-test species list implies. Nature: AI-assisted genome design crosses from theory to practice; first AI-created synthetic virus produced 2025; field described as "generative biology."

Gladstone Institutes (Cell Metabolism): red blood cells absorb large glucose quantities under low-oxygen conditions: a previously unrecognized "glucose sink"; HypoxyStat drug mimicking hypoxia reversed diabetes in mice. UC Riverside (Nature Communications Materials): oxygen-delivering choline-based gel healed chronic wounds in diabetic mice within 23 days; addresses tissue hypoxia without pharmaceuticals. Lawrence Berkeley/Physical Review Letters: thermodynamic computer generates images from thermal noise at orders-of-magnitude less energy than conventional AI systems. Hemochromatosis genetic risk mapped across UK and Ireland for first time; 1 in 54 at risk in northwest Ireland.

UCSF/Wayne State: generative AI matched or outperformed 100+ expert teams on preterm birth prediction; 6-month research cycle vs. ~2 years for original DREAM challenges. UCSF (Cell): liver enzyme GPLD1 repairs blood-brain barrier by trimming TNAP from barrier cells: reversed memory loss in aged mice. Cedars-Sinai (Nature Communications): Chlamydia pneumoniae persists in retina and brain, triggering amyloid-beta buildup; strongest in APOE4 carriers. NbRe alloy shows first experimental signatures of triplet superconductivity (Physical Review Letters); superconducts at 7K. Copenhagen/Niels Bohr: FPGA-based control achieves 100x faster real-time qubit fluctuation tracking. USC: dopamine-producing stem cells implanted in Parkinson's patients. PLOS Medicine: air pollution linked to Alzheimer's risk in 28M older Americans. Oxford (Nature Communications): battery binder visualization could enable faster charging.

Epoxy-oxylipins: body's inflammation off-switch (existing drug accelerates it). Wearable patch monitors drugs via synthetic DNA. DeepRare: 57% diagnostic accuracy (vs 54.6% specialist average). Asgard archaea: oxygen-breathing ancestor of complex life.

DeepMind/Nature: AI moral reasoning reverses with formatting changes.

AI identified 25 new magnetic materials from 67K compounds. Sodium battery: 2x capacity when hydrated, desalinates seawater.

Arc Institute: 260K cancer-specific RNAs across 32 tumor types. Blood test predicted survival from single milliliter. Majorana qubit single-shot readout. DMT single dose reduced depression 2-6 months.

N4BP2 enzyme triggers chromothripsis (25% of cancers).

Neuromorphic computers solve PDEs with fraction of energy. Oxford 154K study: statins don't cause 60+ listed side effects.

Massive star collapsed into black hole (no supernova). Northwestern: lab-grown spinal cord healed injury via "dancing molecules."

QT45 self-replicating RNA (45 nucleotides). Organic compounds on Mars. DMTF1 restores aging neural stem cells.

FDA approved TTFields for pancreatic cancer (first new treatment in 30 years). ACTIVE trial: 5 weeks training cut dementia 25% (20-year follow-up).

Salk: epigenetic atlas of immune cells. Kanzi bonobo: imagination origins pushed back 6-9M years. Universal paralogs predating last common ancestor (~4B years).

Brain MRI AI: seconds for interpretation, 97.5% accuracy.

Mic-628 advances circadian clock (6-hour jet lag recovery in 4 days vs 7). Unified polaron physics models.

TIGERTRIEVER: 86.3% reperfusion (vs 27.7% medical). Fenebrutinib: first oral BTK inhibitor for progressive MS. AlphaFold3 decoded spider silk mechanism.

MARS 19-agent AI lab designed perovskite composite in 3.5 hours. PARM decoded regulatory grammar of human gene promoters. Denitrosylase enzyme: new "fat switch."

ML battery lifetime prediction (months to days). Parkinson's brain network identified. Generate Biomedicines IPO.